Capecitabine, belonging to the class of fluoropyrimidines of chemotherapies, is administered for several cancer types (106), and a phase II trial has shown the combination of lapatinib and capecitabine as a first line treatment for HER2-positive breast cancer (89). Here, ERBB2 is linked to breast carcinoma.